Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
Today we announced that in response to its October 2022 Pre-Request for Designation (Pre-RFD) for our investigational Celularity Tendon Wrap (CTW), the U.S. Food and Drug Administration (FDA) has reviewed information provided by the Company and other relevant available information, and agreed with the Company’s recommendation that its investigational CTW product be regulated as a device by the FDA Center for Devices and Radiologic Health (CDRH).
Today we announced that we have entered into an exclusive distribution agreement with the Tamer Group (“Tamer”). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity’s branded regenerative biomaterial products in Saudi Arabia.
Today we announced that we have entered into an exclusive distribution agreement with the Tamer Group (“Tamer”). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity’s branded regenerative biomaterial products in Saudi Arabia.
Today we announced that we have entered into an exclusive territory distribution agreement with CH Trading Group. CH Trading Group will act as the exclusive territories distributor of Celularity’s previously announced Halal-Certified products within more than 100 countries. The Product Distribution Agreement for Celularity’s Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.
Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
Today we announce that we have received Halal Certification of our business models, commercial stage biomaterial products, and clinical and investigational stage cellular therapeutic programs, indicating that we have undergone rigorous assessment to determine that our innovative solutions are permissible or acceptable in accordance with Islamic, or Sharia, law.
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, are pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells was presented at the renowned Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held in Boston, USA on 8-12 November 2022.
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today reported a corporate update and financial results for the third quarter of 2022.
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it will present preclinical data on the development of its novel placental-derived allogeneic genetically modified natural killer (NK) cell therapy program CYNK-101 in combination with avelumab.
Today we announced the appointment of Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Executive Vice President, Chief Medical Officer (CMO) and Head of Global Medical Affairs, Patient Safety and Patient Affairs. Dr. Kilcoyne brings over 15 years of clinical experience to Celularity, having previously served in R&D, medical affairs, and commercialization roles, primarily focused on oncology. He has a track record of advancing early-stage clinical programs through commercialization and will provide senior leadership to advance Celularity’s clinical pipeline toward U.S. Food and Drug Administration (FDA) approval.
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy
Celularity Announces Clinical Data on Human Placental-derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate CYNK-001 in Adult Patients With Relapsed Refractory And Measurable Residual Disease-positive Acute Myeloid Leukemia
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”
Celularity Inc. Announces $6 Million Registered Direct Offering
Celularity Announces Acceptance of Poster Presentation at 2023 Society For Biomaterials Annual Meeting
Celularity Receives U.S. Food and Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt
Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders For Celularity Branded Halal-Certified Biomaterial Products
Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction For Its Investigational Celularity Tendon Wrap (CTW) To Be Regulated As A Device Within U.S. Food and Drug Administration (FDA) Center For Devices and Radiological Health (CDRH)
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-up and Pipeline Prioritization of Next-Generation Product Candidates
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Celularity Appoints Paul Graves as Chief Communications Officer
Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
Celularity Promotes Two Executives in Executive Leadership Team
Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer